Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...

A health system–wide lipid screening pathway significantly increased pediatric screening rates across a large primary care network. A structured, system-wide clinical pathway increased pediatric lipid ...

Meeting the needs of the community is one of North Idaho College President Nick Swayne’s main goals. So when he saw a growing trend toward classical education in the Inland Northwest with charter, ...

Abstract: The paper develops a Personalized Adaptive Learning Pathway System (PALPS) which adaptively designs streamlined educational programs for compiler design courses. The system deals with three ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

ARCHER II trial evaluates vonaprument's efficacy in preventing vision loss in advanced AMD/GA, with over 630 patients enrolled globally. Vonaprument selectively inhibits C1q, addressing ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...